Nuclear magnetic resonance

Bioxytran Releases Positive Top-line Results from Phase 2 Trial of Galectin Antagonist on COVID-19 Patients in medRxiv Pre-print

Retrieved on: 
Wednesday, November 16, 2022
Preprint, Workplace, Technology, COVID, OTCQB, PCR, Nuclear magnetic resonance, Population, Knowledge, Carbohydrate, Pulmonary fibrosis, Galectin, Safety, Degenerative disease, Ventilation, Virology, Hypoxia, SAE, NMR, Patient, Mask, COVID-19, COVID19, Virus, Clinical trial, Stroke, Immune system, Science, Vaccine, Disease, Viral load, Pharmaceutical industry, Long COVID

BOSTON, Nov. 16, 2022 /PRNewswire/ -- BIOXYTRAN, INC. (OTCQB: BIXT), (the "Company"), a clinical stage biotechnology company developing oral drugs to treat COVID-19 and other viral diseases, announced positive topline safety and efficacy results of its randomized, placebo-controlled Phase 2 clinical trial in 34 patients with mild-to-moderate COVID-19.  During the 7 days of treatment, an orally administered Galectin Antagonist in the form of a chewable tablet was administered 8 times per day on an hourly basis. The endpoint was a statistically significant reduction in viral load measured by the number of patients reaching a below threshold PCR value (Ct value ≥ 29) by day 7.  The trial met its endpoint with a 100% response rate by day 7 versus 6% in placebo, which was statistically significant (p-value = .001).  Our analysis also revealed an 88% response rate by day 3, which was statistically significant (p-value = .001). There were no drug-related serious adverse events (SAE's) in the patient population or viral rebounds by day 14 in the patient population. The positive data from this clinical trial provided the rationale of dosing and protocol design for study in an upcoming phase 2/3 registrational trial. 

Key Points: 
  • There were no drug-related serious adverse events (SAE's) in the patient population or viral rebounds by day 14 in the patient population.
  • The positive data from this clinical trial provided the rationale of dosing and protocol design for study in an upcoming phase 2/3 registrational trial.
  • Nuclear Magnetic Resonance ("NMR") testing was used to elucidate the Mechanism of Action of the specific Galectin Antagonist.
  • While the Galectin Antagonist does indeed bind to the S1 Spike Protein, the study showed that it could bind in 2 different orientations with galectin-3.

Nanalysis Announces Third Quarter 2022 Conference Call

Retrieved on: 
Tuesday, November 15, 2022
Conference, Technology, Nuclear magnetic resonance, Acquisition, Government, Intention, News, Daou Technology Inc., Forward-looking statement, AB, TSX Venture Exchange, Q&A, NSCI, Industry, The Company, Interim, View, Company, Ownership, Law enforcement, Mining, Multimedia, NMR, FRA, Food, Nanalysis, MRI, OTC, Agrochemical, OTCQX, Financial services, Medical imaging

Investors interested in participating on the live second quarter call can dial 1-888-664-6392 or 416-764-8659 from abroad.

Key Points: 
  • Investors interested in participating on the live second quarter call can dial 1-888-664-6392 or 416-764-8659 from abroad.
  • The webcast will be archived on the Company's investor relations webpage for at least 90 days and a telephonic playback will be available for seven days after the conference call by calling 1-888-390-0541 or 416-764-8677, conference ID #833132.
  • Nanalysis trades on the TSX Venture Exchange (TSXV) inCanadawith ticker symbol 'NSCI', OTC and theFrankfurtexchange under the ticker symbol '1N1'.
  • Neither TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

Nanalysis to Present at LD Micro Main Event XV Investor Conference Presentation is Tuesday, Oct. 25th at 2:00pm PT

Retrieved on: 
Tuesday, October 18, 2022
News, FSE, Government, Nuclear magnetic resonance, Conference, Nanalysis, MRI, Technology, Company, Acquisition, Industry, TSX Venture Exchange, Law enforcement, CEO, Intention, Agrochemical, OTC, Food, Forward-looking statement, NSCI, Ownership, NMR, Mining, Medical imaging, Fine chemical

Nanalysis CEO Sean Krakiwsky will be presenting at the LD Micro Conference in Los Angeles on Tuesday, Oct. 25th at 2:00pm PT in Track 2.

Key Points: 
  • Nanalysis CEO Sean Krakiwsky will be presenting at the LD Micro Conference in Los Angeles on Tuesday, Oct. 25th at 2:00pm PT in Track 2.
  • Mr. Krakiwsky will be available in person for 1x1 meetings on Tuesday, Oct 25th and Wednesday, Oct 26th.
  • Nanalysis trades on the TSX Venture Exchange (TSXV) in Canada with ticker symbol 'NSCI', OTC and the Frankfurt exchange under the ticker symbol '1N1'.
  • Neither TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

Nanalysis Provides Corporate Update

Retrieved on: 
Thursday, October 20, 2022
News, Government, Nuclear magnetic resonance, Growth, Conference, Multimedia, MRI, Technology, Airport, Company, FRA, Mining, CATSA, Industry, Acquisition, TSX Venture Exchange, Law enforcement, CEO, Intention, Agrochemical, OTCQX, OTC, Food, Security, Forward-looking statement, NSCI, AB, Security Service, Ownership, The Company, Party, NMR, View, Medical imaging, Pharmaceutical industry, Video game, Fine chemical, Quad, Nanalysis

Presenting at LD Micro Conference on Oct. 25th

Key Points: 
  • Presenting at LD Micro Conference on Oct. 25th
    CALGARY, AB, Oct. 20, 2022 /PRNewswire/ - Nanalysis Scientific Corp. ("the Company", TSXV: NSCI , OTCQX: NSCIF , FRA: 1N1 ), a leader in portable NMR machines and MRI technology for healthcare and industrial applications, provides a corporate update on operations.
  • "We have seen a strong return to our growth trajectory in our core NMR business," saidSean Krakiwsky, Founder and CEO of Nanalysis.
  • Nanalysis CEO Sean Krakiwsky will be presenting at the LD Micro Conference in Los Angeles on Tuesday, Oct. 25th at 2:00pm PT in Track 2.
  • Nanalysis trades on the TSX Venture Exchange (TSXV) inCanadawith ticker symbol 'NSCI', OTC and theFrankfurtexchange under the ticker symbol '1N1'.

Lifespin Announces Expansion of Laboratory Testing Capability

Retrieved on: 
Tuesday, September 20, 2022
Technology, Medical Devices, Professional Services, Software, Biotechnology, Data Analytics, Pharmaceutical, Health, Data Management, Oncology, NMR, Health, Inflammation, RUO, Precision medicine, Fluid mechanics, Metabolomics, Database, Cell biology, Nuclear magnetic resonance, Maintenance, CEO, CT, Yale University, Neurology, Multimedia, Medical imaging

Lifespin GmbH, based in Regensburg (Germany), with offices in Boston, Massachusetts, announced today that it has installed additional Nuclear Magnetic Resonance (NMR) equipment which will double Lifespins annual laboratory testing capacity.

Key Points: 
  • Lifespin GmbH, based in Regensburg (Germany), with offices in Boston, Massachusetts, announced today that it has installed additional Nuclear Magnetic Resonance (NMR) equipment which will double Lifespins annual laboratory testing capacity.
  • View the full release here: https://www.businesswire.com/news/home/20220920005212/en/
    Lifespin's scalability enables the firm to cost-effectively process 300,000 patient metabolic health samples a year with rapid turnaround.
  • (Graphic: Business Wire)
    Lifespin will now be able to scan and create the corresponding digitized, quantitative metabolic profiles involving as many as 300,000 human samples per year.
  • Utilizing proprietary technology, Lifespin is performing quantitative in-house measurements of metabolomes, digitizing metabolic profiles that include billions of metabolic relationships.

Nanalysis Scientific Corp. Announces Grant of Stock Options

Retrieved on: 
Tuesday, August 30, 2022
Nanalysis, Mining, AB, Food, Agrochemical, Nuclear magnetic resonance, OTC, Government, Ownership, Board, TSX Venture Exchange, Multimedia, Intention, Board of directors, Company, News, FRA, MRI, Special-purpose acquisition company, Law enforcement, NMR, Acquisition, Industry, Forward-looking statement, NSCI, Security (finance), Medical imaging, Fine chemical

CALGARY, AB, Aug. 30, 2022 /PRNewswire/ - Nanalysis Scientific Corp. (TSXV:NSCI) (OTCQX: NSCIF) (FRA: 1N1) ("Nanalysis" or the "Company") announces that the Company's Board of Directors has granted a total of 377,500 stock options to its employees, including 175,000 to an officer, pursuant to the Company's stock option plan.

Key Points: 
  • CALGARY, AB, Aug. 30, 2022 /PRNewswire/ - Nanalysis Scientific Corp. (TSXV:NSCI) (OTCQX: NSCIF) (FRA: 1N1) ("Nanalysis" or the "Company") announces that the Company's Board of Directors has granted a total of 377,500 stock options to its employees, including 175,000 to an officer, pursuant to the Company's stock option plan.
  • The options vest as to one-third on each of the 12 month, 24 month and 36 month anniversary date of grant.
  • Nanalysis trades on the TSX Venture Exchange (TSXV) inCanadawith ticker symbol 'NSCI', OTC and theFrankfurtexchange under the ticker symbol '1N1'.
  • Nanalysis recently announced that it has begun selling a 100MHz device in 2020.

Nanalysis Announces Second Quarter 2022 Conference Call

Retrieved on: 
Wednesday, August 10, 2022
Q&A, Multimedia, Interim, AB, Industry, Forward-looking statement, NSCI, The Company, Technology, TSX Venture Exchange, Law enforcement, Government, Nuclear magnetic resonance, Daou Technology Inc., Company, Food, Acquisition, Nanalysis, View, OTC, FRA, Intention, News, Ownership, NMR, Agrochemical, Conference, MRI, Mining, Financial services, Medical imaging

Investors interested in participating on the live second quarter call can dial 1-888-664-6392 or 416-764-8659 from abroad.

Key Points: 
  • Investors interested in participating on the live second quarter call can dial 1-888-664-6392 or 416-764-8659 from abroad.
  • The webcast will be archived on the Company's investor relations webpage for at least 90 days and a telephonic playback will be available for seven days after the conference call by calling 1-888-390-0541 or 416-764-8677, conference ID #484317.
  • Nanalysis trades on the TSX Venture Exchange (TSXV) inCanadawith ticker symbol 'NSCI', OTC and theFrankfurtexchange under the ticker symbol '1N1'.
  • Neither TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

Nanalysis Scientific Corp. Announces Management Transitions

Retrieved on: 
Thursday, July 21, 2022
CA, MRI, LLP, Acquisition, Food, CFO, University, TSX Venture Exchange, Randall, Industry, Daou Technology Inc., Forward-looking statement, AB, Government, Hotel manager, Solution, Intention, Ownership, Randalls, Agrochemical, Institute, Commerce, Board, Partner, NMR, News, Mining, MNP, FRA, Director, Technology, Company, Nuclear magnetic resonance, NSCI, Law enforcement, Market for corporate control, CPA, Entrepreneurship, Growth, Automation, OTC, Audit, Nanalysis

CALGARY, AB, July 21, 2022 /PRNewswire/ - Nanalysis Scientific Corp. (TSXV:NSCI) (OTCQX: NSCIF) (FRA: 1N1) ("Nanalysis" or the "Company") announces that the current CFO, Luke Caplette, is stepping down as CFO, but will remain with the Company as a part-time consultant to assist the transition to a new CFO.

Key Points: 
  • CALGARY, AB, July 21, 2022 /PRNewswire/ - Nanalysis Scientific Corp. (TSXV:NSCI) (OTCQX: NSCIF) (FRA: 1N1) ("Nanalysis" or the "Company") announces that the current CFO, Luke Caplette, is stepping down as CFO, but will remain with the Company as a part-time consultant to assist the transition to a new CFO.
  • "We wish to thank Luke for his tremendous contribution to Nanalysis as CFO over the last three years.
  • "Randall has worked for Nanalysis for the past six months as a consultant and will provide solid continuity during this transition.
  • Nanalysis trades on the TSX Venture Exchange ("TSXV") inCanadawith ticker symbol 'NSCI', OTC and theFrankfurtexchange under the ticker symbol '1N1'.

Nanalysis Announces Results of AGM and Appointment of New Director

Retrieved on: 
Thursday, June 23, 2022
Industry, Ernst & Young, View, Government, Meeting, Company, OTC, Forward-looking statement, Ownership, Metrohm, Intention, NSCI, Acquisition, News, Mining, MRI, Food, Nanalysis, TSX Venture Exchange, Board of directors, NMR, Law enforcement, Agrochemical, Board, Agilent Technologies, Multimedia, Nuclear magnetic resonance, Medical imaging, Fine chemical, Audit, Leidos

Mr. Lin is currently a Managing Director at Nanalysis and was formerly the President and Chief Executive Officer of KPrime Technologies before the Company's acquisition by Nanalysis.

Key Points: 
  • Mr. Lin is currently a Managing Director at Nanalysis and was formerly the President and Chief Executive Officer of KPrime Technologies before the Company's acquisition by Nanalysis.
  • KPrime has a portfolio of sales and services in scientific detection and measuring equipment, financing, and asset management for chemical and security industries.
  • Mr. Lin resides and works in Calgary, Alberta, Canada but also splits time in Phoenix, Arizona at KPrime Headquarters.
  • Nanalysis trades on the TSX Venture Exchange (TSXV) inCanadawith ticker symbol 'NSCI', OTC and theFrankfurtexchange under the ticker symbol '1N1'.

Proteum Energy® Collaborates with University of Regina to Enhance Production of Hydrogen from Ethanol Feedstock

Retrieved on: 
Thursday, June 9, 2022
Oil, Gas, Alternative Energy, Energy, Science, Research, Nuclear magnetic resonance, Treaty 4, LLC, Transport, II, Government, Ethanol, University, Student, Cree, Technology, CCS, Nakoda, Gasoline, University of Regina, Industry, Lakota, Renewable energy, Hydrogen, Mitacs

Proteum Hydrogen Technologies Corp., a subsidiary of Proteum Energy, LLC, and the University of Regina have embarked on a joint project aimed at advancing Proteums patented and proprietary steam non-methane reforming (SnMR) technology.

Key Points: 
  • Proteum Hydrogen Technologies Corp., a subsidiary of Proteum Energy, LLC, and the University of Regina have embarked on a joint project aimed at advancing Proteums patented and proprietary steam non-methane reforming (SnMR) technology.
  • The project, conducted through the Universitys Clean Energy Technologies Research Institute (CETRI), focuses on optimizing performance of Proteums commercial system for production of hydrogen from renewable ethanol feedstock.
  • We are pleased and excited to work with such a prestigious research university to enhance hydrogen yields for our projects utilizing ethanol feedstock.
  • About Proteum Energy Headquartered in Phoenix Arizona, Proteum is a producer of low-cost, clean hydrogen from residue gas and renewable ethanol.